CARVYKTI 3.2 × 10^6 – 1 × 10^8 cells dispersion for infusion

  • DHPC
Company
Janssen Sciences Ireland (a Johnson & Johnson Company)
Active Ingredient
Dosage Form
Dispersion for infusion
Legal Category
A - prescription, may not be renewed
Date of revision
10/2026

*further information is available on request to the holder of the authorisation or in the SPC

Direct Healthcare Professional Communications

  • DHPC - CD19 or BCMA directed CAR T-cell therapies – Risk of secondary malignancy of T-cell origin

    Direct Healthcare Professional Communication (DHPC)

    PDF627.68 KB

Janssen Sciences Ireland (a Johnson & Johnson Company)

Janssen Sciences Ireland UC, Barnahely, Ringaskiddy, IRL - Co. Cork P43 FA46, P43 FA46 Ringaskiddy

Website
https://innovativemedicine.jnj.com/ireland/
Telephone
+3531800709122
Email
medinfo@its.jnj.com